%0 Journal Article
%T Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board
%J -
%D 2019
%R https://doi.org/10.1016/j.it.2018.12.009
%X Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group ( Cell 2018;175:1731¨C1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory
%U https://www.cell.com/trends/immunology/fulltext/S1471-4906(18)30248-5